CANTON, Mass., April 17, 2012 /PRNewswire/ -- Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that Apligraf® has established improved coverage from multiple ...
More than three million United States adults suffer from venous ulcers, suggested a new report from THE SAGE GROUP. The cost of venous disease represents a significant burden on patients and the U.S.
Apligraf® - an FDA-approved, bioengineered living-cell therapy from Organogenesis Inc. - has become the first wound-healing therapy to demonstrate a significant change in the genomic profile of a ...
Medicare's decision to slash the cost of wound-care products is shoving the regenerative medicine company Organogenesis toward a major restructuring, with the CEO conceding to staffers that "heart ...
Biotherapeutic Cell-based Product from Organogenesis Meets Switzerland's Highest Clinical and Safety Standards Apligraf is a biotherapeutic wound-healing technology that contains two layers of human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results